Brimonidine and brinzolamide for treating glaucoma and ocular hypertension; a safety evaluation

References

• Cantor LB. Brimonidine in the treatment of glaucoma and ocular hypertension. Ther Clin Risk Manag. 2006;2:337–346.
   PubMedGoogle Scholar
• Cantor LB, WuDunn D, Catoira-Boyle Y, et al. Absorption of brimonidine 0.1% and 0.15% ophthalmic solutions in the aqueous humor of cataract patients. J Glaucoma. 2008;17:529–534.
   PubMed Web of Science ®Google Scholar
• Cantor LB, Safyan E, Liu CC, et al. Brimonidine-purite 0.1% versus brimonidine-purite 0.15% twice daily in glaucoma or ocular hypertension: a 12-month randomized trial. Curr Med Res Opin. 2008;24:2035–2043.
   PubMed Web of Science ®Google Scholar
• Arthur S, Cantor LB. Update on the role of alpha-agonists in glaucoma management. Exp Eye Res. 2011;93(3):271–283.
   PubMed Web of Science ®Google Scholar
• Cantor LB. The evolving pharmacotherapeutic profile of brimonidine, an alpha 2-adrenergic agonist, after four years of continuous use. Expert Opin Pharmacother. 2000;1:815–834.
   PubMedGoogle Scholar
• Schuman JS, Horwitz B, Choplin NT, et al. A 1-year study of brimonidine twice daily in glaucoma and ocular hypertension. A controlled, randomized, multicenter clinical trial. Arch Ophthalmol. 1997;115:847–852.
   PubMed Web of Science ®Google Scholar
• Katz LJ. Brimonidine Study Group. Brimonidine tartrate 0.2% twice daily vs timolol 0.5% twice daily: 1-year results in glaucoma patients. Am J Ophthalmol. 1999;127:20–26.
   PubMed Web of Science ®Google Scholar
• Goldberg I, Crowston JG, Jasek MC, et al.; ADAPT Study Investigator Group. Intraocular pressure-lowering efficacy of brinzolamide when added to travoprost/timolol fixed combination as adjunctive therapy. J Glaucoma. 2012;21:55–59.
   PubMed Web of Science ®Google Scholar
• Michaud JE, Friren B. Comparison of topical brinzolamide 1% and dorzolamide 2% eye drops given twice daily in addition to timolol 0.5% in patients with primary open-angle glaucoma or ocular hypertension. Am J Ophthalmol. 2001;132:235–243.
   PubMed Web of Science ®Google Scholar
• March WF, Ochsner KI. The long-term safety and efficacy of brinzolamide 1.0% (Azopt) in patients with primary open-angle glaucoma or ocular hypertension. Am J Ophthalmol. 2000;129:136–143.
   PubMed Web of Science ®Google Scholar
• Silver LH. Clinical efficacy and safety of brinzolamide (Azopt), a new topical carbonic anhydrase inhibitor for primary open-angle glaucoma and ocular hypertension. Am J Ophthalmol. 1998;126:400–408.
   PubMed Web of Science ®Google Scholar
• Stewart WC, Kolker AE, Sharpe ED, et al. Long-term progression at individual mean intraocular pressure levels in primary open-angle and exfoliative glaucoma. Eur J Ophthalmol. 2008;18:765–770.
   PubMed Web of Science ®Google Scholar
• Gordon MO, Kass MA. The Ocular Hypertension Treatment Study: design and baseline description of the participants. Arch Ophthalmol. 1999;117:573–583.
   PubMed Web of Science ®Google Scholar
• Anderson DR. Collaborative normal tension glaucoma study. Curr Opin Ophthalmol. 2003;14:86–90.
   PubMedGoogle Scholar
• Leske MC, Heijl A, Hyman L, et al. Early manifest glaucoma trial: design and baseline data. Ophthalmology. 1999;106:2144–2153.
   PubMed Web of Science ®Google Scholar
• Ederer F, Gaasterland DE, Sullivan EK, et al. The advanced glaucoma intervention study (AGIS): 1. Study design and methods and baseline characteristics of study patients. Control Clin Trials. 1994;15:299–325.
   PubMedGoogle Scholar
• Musch DC, Lichter PR, Guire KE, et al. The collaborative initial glaucoma treatment study: study design, methods, and baseline characteristics of enrolled patients. Ophthalmology. 1999;106:653–662.
   PubMed Web of Science ®Google Scholar
• Foster PJ, Buhrmann R, Quigley HA, et al. The definition and classification of glaucoma in prevalence surveys. Br J Ophthalmol. 2002;86(2):238–242.
   PubMed Web of Science ®Google Scholar
• Mantravadi AV, Vadhar N. Glaucoma. Prim Care Clin Office Pract. 2015;42:437–449.
   PubMed Web of Science ®Google Scholar
• Pascolini D, Mariotti SP. Global estimates of visual impairment: 2010. Br J Ophthalmol. 2012;96:614–618.
   PubMed Web of Science ®Google Scholar
• Kingman S. Glaucoma is second leading cause of blindness globally. Bull World Health Organ. 2004;82(11):887–888.
   PubMed Web of Science ®Google Scholar
• Peters D, Bengtsson B, Heijl A. Factors associated with lifetime risk of open-angle glaucoma blindness. Acta Ophthalmol. 2014;92:421–425.
   PubMed Web of Science ®Google Scholar
• Stewart WC, Stewart JA, Nelson LA, et al. Physician attitudes regarding prostaglandin treatment for glaucoma in the United States and Europe. Eur J Ophthalmol. 2008;18:199–204.
   PubMed Web of Science ®Google Scholar
• Stein JD, Ayyagari P, Sloan FA, et al. Rates of glaucoma medication utilization among persons with primary open-angle glaucoma 1992 to 2002. Ophthalmology. 2008;115:1315–1319.
   PubMed Web of Science ®Google Scholar
• Sambhara D, Aref AA. Glaucoma management: relative value and place in therapy of available drug treatments. Ther Adv Chronic Dis. 2014;5(1):30–43.
   PubMedGoogle Scholar
• Webers CA, Beckers HJ, Nuijts RM, et al. Pharmacological management of primary open-angle glaucoma: second-line options and beyond. Drugs Aging. 2008;25:729–759.
   PubMed Web of Science ®Google Scholar
• Kass MA, Heuer DK, Higginbotham EJ, et al. The Ocular Hypertension Treatment Study: a randomized trial determines that topical ocular hypotensive medication delays or prevents the onset of primary open-angle glaucoma. Arch Ophthalmol. 2002;120(6):701–713.
   PubMed Web of Science ®Google Scholar
• Boger WP. 3rd. Short-term “escape” and long-term “drift”. The dissipation effects of the beta adrenergic blocking agents. Surv Ophthalmol. 1983;28(Suppl):235–242.
   PubMedGoogle Scholar
• Sharma S, Trikha S, Perera S, et al. Clinical effectiveness of brinzolamide 1%-brimonidine 0.2% fixed combination for primary open-angle glaucoma and ocular hypertension. Clin Ophthalmol. 2015;9:2201–2207.
   PubMed Web of Science ®Google Scholar
• Nguyen QH. Combination of brinzolamide and brimonidine for glaucoma and ocular hypertension: critical appraisal and patient focus. Patient Prefer Adherence. 2014;8:853–864.
   PubMed Web of Science ®Google Scholar
• Burke J, Schwartz M. Preclinical evaluation of brimonidine. Surv Ophthalmol. 1996;41(suppl 1):S9–18.
   PubMed Web of Science ®Google Scholar
• Liu CJ, Cheng CY, Ko YC, et al. Diurnal intraocular pressure and blood pressure with two dosing regimens of brimonidine in normal tension glaucoma. J Chin Med Assoc. 2004;67:465–471.
   PubMedGoogle Scholar
• Toris CB, Gleason ML, Camras CB, et al. Effects of brimonidine on aqueous humor dynamics in human eyes. Arch Ophthalmol. 1995;113:1514–1517.
   PubMed Web of Science ®Google Scholar
• Toris CB, Camras CB, Yablonski ME. Effects of brimonidine on aqueous humor dynamics in human eyes. Arch Ophthalmol. 1995;113:1514–1517.
   PubMed Web of Science ®Google Scholar
• Walters TR. Development and use of brimonidine in treating acute and chronic elevations of intraocular pressure: a review of safety, efficacy, dose response, and dosing studies. Surv Ophthalmol. 1996;41(Suppl 1):S19–26.
   PubMed Web of Science ®Google Scholar
• Yoles E, Wheeler LA, Schwartz M. Alpha2-adrenoreceptor agonists are neuroprotective in a rat model of optic nerve degeneration. Invest Ophthalmol Vis Sci. 1999;40:65–73.
   PubMed Web of Science ®Google Scholar
• WoldeMussie E, Ruiz G, Wijono M, et al. Neuroprotection of retinal ganglion cells by brimonidine in rats with laser-induced chronic ocular hypertension. Invest Ophthalmol Vis Sci. 2001;42:2849–2855.
   PubMed Web of Science ®Google Scholar
• Donello JE, Padillo EU, Webster ML, et al. Alpha2-Adrenoceptor agonists inhibit vitreal glutamate and aspartate accumulation and preserve retinal function after transient ischemia. J Pharmacol Exp Ther. 2001;296:216–223.
   PubMed Web of Science ®Google Scholar
• Weinreb RN, Levin LA. Is neuroprotection a viable therapy for glaucoma? Arch Ophthalmol. 1999;117:1540–1544.
   PubMed Web of Science ®Google Scholar
• Krupin T, Liebmann JM, Greenfield DS, et al. A randomized trial of brimonidine versus timolol in preserving visual function: results from the low-pressure glaucoma treatment study. Am J Ophthalmol. 2011;151:671–681.
   PubMed Web of Science ®Google Scholar
• Fan N, Wang P, Tang L, et al. Ocular blood flow and normal tension glaucoma. Biomed Res Int. 2015. Epub Oct 19.
   Web of Science ®Google Scholar
• Gramer G, Weber BH, Gramer E. Migraine and vasospasm in glaucoma: age-related evaluation of 2027 patients with glaucoma or ocular hypertension. Invest Ophthalmol Vis Sci. 2015;56(13):7999–8007.
   PubMed Web of Science ®Google Scholar
• Kaiser HJ, Schoetzau A, Stump D, et al. Blood flow velocities of the extraocular vessels in patients with high-tension and normal-tension primary open-angle glaucoma. Am J Ophthalmol. 1997;123(3):320–327.
   PubMed Web of Science ®Google Scholar
• David R. Brimonidine (Alphagan): a clinical profile four years after launch. Eur J Ophthalmol. 2001;11(Suppl 2):S72–7.
   PubMed Web of Science ®Google Scholar
• Tsumura T, Yoshikawa K, Kimura T, et al. The efficacy and safety of add-on 0.1% brimonidine tartrate preserved with sodium chlorite in on-treatment Japanese normal-tension glaucoma patients. Clin Ophthalmol. 2014;8:1681–1687.
   PubMedGoogle Scholar
• Lee AJ, McCluskey P. Fixed combination of topical brimonidine 0.2% and timolol 0.5% for glaucoma and uncontrolled intraocular pressure. Clin Ophthalmol. 2008;2(3):545–555.
   PubMedGoogle Scholar
• Galanopoulos A, Goldberg I. Clinical efficacy and neuroprotective effects of brimonidine in the management of glaucoma and ocular hypertension. Clin Ophthalmol. 2009;3:117–122.
   PubMedGoogle Scholar
• Blondeau P, Rousseau JA. Allergic reactions to brimonidine in patients treated for glaucoma. Can J Ophthalmol. 2002;37:21–26.
   PubMed Web of Science ®Google Scholar
• Nguyen EV, Azar D, Papalkar D, et al. Brimonidine-induced anterior uveitis and conjunctivitis: clinical and histologic features. J Glaucoma. 2008;17:40–42.
   PubMed Web of Science ®Google Scholar
• Katz LJ. Twelve-month evaluation of brimonidine-purite versus brimonidine in patients with glaucoma or ocular hypertension. J Glaucoma. 2002;11:119–126.
   PubMed Web of Science ®Google Scholar
• Manufacturer’s information: brimonidine tartrate ophthalmic solution, 0.15% product monograph. Fort Worth (TX): Alcon Ophthalmics; 2013 Sep.
   Google Scholar
• Berlin RJ, Lee UT, Samples JR, et al. Ophthalmic drops causing coma in an infant. J Pediatr. 2001;138:441–443.
   PubMed Web of Science ®Google Scholar
• Daubert GP. Is brimonidine ophthalmic a safe therapy for infants? J Clin Pharm Ther. 2006;31:289–292.
   PubMed Web of Science ®Google Scholar
• Al-Shahwan S, Al-Torbak AA, Turkmani S, et al. Side-effect profile of brimonidine tartrate in children. Ophthalmology. 2005;112(2):2143.
   PubMed Web of Science ®Google Scholar
• Yoshidaa M, Okadaa E, Mizuki N, et al. Age-specific prevalence of open-angle glaucoma and its relationship to refraction among more than 60,000 asymptomatic Japanese subjects. J Clin Epidemiol. 2001;54:1151–1158.
   PubMed Web of Science ®Google Scholar
• Salim S. Glaucoma in pregnancy. Curr Opin Ophthalmol. 2014;25:93–97.
   PubMed Web of Science ®Google Scholar
• Sethi HS, Naik M, Gupta VS. Management of glaucoma in pregnancy: risks or choices, a dilemma? Int J Ophthalmol. 2016;9(11):1684–1690.
   PubMed Web of Science ®Google Scholar
• Coleman AL, Mosaed S, Kamal D. Medical therapy in pregnancy. J Glaucoma. 2005;14:414–416.
   PubMed Web of Science ®Google Scholar
• Goldenberg MM. Pharmaceutical approval update. Pharm Ther. 2013;38(6):323–324.
   Google Scholar
• Li T, Lindsley K, Rouse B, et al. Comparative effectiveness of first-line medications for primary open angle glaucoma – a systematic review and network meta-analysis. Ophthalmology. 2016;123(1):129–140.
   PubMed Web of Science ®Google Scholar
• Butler P, Mannschreck M, Lin S, et al. Clinical experience with the long-term use of 1% apraclonidine. Incidence of allergic reactions. Arch Ophthalmol. 1995;113:293–296.
   PubMed Web of Science ®Google Scholar
• Feibel RM. High incidence of topical allergic reactions to 1% apraclonidine. Arch Ophthalmol. 1995;113:1579–1580.
   PubMedGoogle Scholar
• Wright TM, Freedman SF. Exposure to topical apraclonidine in children with glaucoma. J Glaucoma. 2009;18(5):395–398.
   PubMed Web of Science ®Google Scholar
• Inoue K, Shiokawa M, Sugahara M, et al. Iris and periocular adverse reactions to bimatoprost in Japanese patients with glaucoma or ocular hypertension. Clin Ophthalmol. 2012;6:111–116.
   PubMedGoogle Scholar
• Johnstone MA. Hypertrichosis and increased pigmentation of eyelashes and adjacent hair in the region of the ipsilateral eyelids of patients treated with unilateral topical latanoprost. Am J Ophthalmol. 1997;124(4):544–547.
   PubMed Web of Science ®Google Scholar
• Johnstone MA, Albert DM. Prostaglandin-induced hair growth. Surv Ophthalmol. 2002;47(Suppl 10):S185–S202.
   PubMed Web of Science ®Google Scholar
• Sakata R, Shirato S, Miyata K, et al. Incidence of deepening of the upper eyelid sulcus in prostaglandin-associated periorbitopathy with a latanoprost ophthalmic solution. Eye. 2014;28:1446–1451.
   PubMed Web of Science ®Google Scholar
• Zhang WY, Po AL, Dua HS, et al. Meta-analysis of randomised controlled trials comparing latanoprost with timolol in the treatment of patients with open angle glaucoma or ocular hypertension. Br J Ophthalmol. 2001;85:983–990.
   PubMed Web of Science ®Google Scholar
• Schuman JS. Effects of systemic beta-blocker therapy on the efficacy and safety of topical brimonidine and timolol. Ophthalmology. 2000;107:1171–1177.
   PubMed Web of Science ®Google Scholar
• Supuran C. Drug interaction considerations in the therapeutic use of carbonic anhydrase inhibitors. Expert Opin Drug Metab Toxicol. 2016;12(4):423–431.
   PubMed Web of Science ®Google Scholar
• Supuran C. Carbonic anhydrases: novel therapeutic applications for inhibitors and activators. Nature Rev Drug Discov. 2008;7:168–181.
   PubMed Web of Science ®Google Scholar
• Sugrue MF. The preclinical pharmacology of dorzolamide hydrochloride, a topical carbonic anhydrase inhibitor. J Ocul Pharmacol Ther. 1996;12:363–376.
   PubMed Web of Science ®Google Scholar
• Lester M. Brinzolamide ophthalmic suspension: a review of its pharmacology and use in the treatment of open angle glaucoma and ocular hypertension. Clin Ophthalmol. 2008;2(3):517–523.
   PubMedGoogle Scholar
• Dean T, May J, Chen HH, et al. Brinzolamide (AL-4862) suspension is a new topically active carbonic anhydrase inhibitor in the Dutch-belted rabbits and cynomolgus monkey. Invest Ophthalmol Vis Sci. 1997;38(suppl):S813.
   Google Scholar
• Wang TH, Huang JY, Hung PT, et al. Ocular hypotensive effect and safety of brinzolamide ophthalmic solution in open angle glaucoma patients. J Formos Med Assoc. 2004;103:369–373.
   PubMed Web of Science ®Google Scholar
• Van der Valk R, Webers CAB, Schouten JSAG, et al. Intraocular pressure-lowering effects of all commonly used glaucoma drugs. Meta-Anal Randomized Clin Trials Ophthalmol. 2005;112:1177–1185.
   Google Scholar
• Shin D. The Brinzolamide Adjunctive Therapy Study Group. Adjunctive therapy with brinzolamide 1% ophthalmic suspension (AZOPT) in patients with open-angle glaucoma or ocular hypertension maintained on timolol therapy. Surv Ophthalmol. 2000;44(4 suppl 2):163–168.
   Web of Science ®Google Scholar
• Inoue K, Shiokawa M, Ishida K, et al. Safety and efficacy of switching from dorzolamide 1.0%/timolol maleate 0.5% eye drops to brinzolamide 1.0%/timolol maleate 0.5% eye drops. Clin Ophthalmol. 2015;9:619–623.
   PubMed Web of Science ®Google Scholar
• Cheng J-W, Cheng S-W, Gao L-D, et al. Intraocular pressure-lowering effects of commonly used fixed-combination drugs with timolol: a systematic review and meta-analysis. PLoS One. 2012;7(9):e45079.
   PubMed Web of Science ®Google Scholar
• Lanzl I, Raber T. Efficacy and tolerability of the fixed combination of brinzolamide 1% and timolol 0.5% in daily practice. Clin Ophthalmol. 2011;5:291–298.
   PubMedGoogle Scholar
• Manni G, Denis P, Chew P, et al. The safety and efficacy of brinzolamide 1%/timolol 0.5% fixed combination versus dorzolamide 2%/timolol 0.5% in patients with open-angle glaucoma or ocular hypertension. J Glaucoma. 2009;18(4):293–300.
   PubMed Web of Science ®Google Scholar
• Skalicky SE, Goldberg I, McCluskey P. Ocular surface disease and quality of life in patients with glaucoma. Am J Ophthalmol. 2012;153(1):1–9.e2.
   PubMed Web of Science ®Google Scholar
• DeSantis L. Preclinical overview of brinzolamide. Surv Ophthalmol. 2000;44(Suppl 2):S119–29.
   PubMed Web of Science ®Google Scholar
• Zhao JC, Chen T. Brinzolamide induced reversible corneal decompensation. Br J Ophthalmol. 2005;89:389–390.
   PubMed Web of Science ®Google Scholar
• Menon GJ, Vernon SA. Topical brinzolamide and metabolic acidosis. Br J Ophthalmol. 2006;90:247–248.
   PubMed Web of Science ®Google Scholar
• Strom BL, Schinnar R, Apter AJ, et al. Absence of cross-reactivity between sulfonamide antibiotics and sulfonamide nonantibiotics. N Engl J Med. 2003;349:1628–1635.
   PubMed Web of Science ®Google Scholar
• Guedes GB, Karan A, Mayer HR, et al. Evaluation of adverse events in self-reported sulfa-allergic patients using topical carbonic anhydrase inhibitors. J Ocul Pharmacol Ther. 2013;29(5):456–461.
   PubMed Web of Science ®Google Scholar
• Whitson JT, Roarty JD, Vijaya L, et al. Efficacy of brinzolamide and levobetaxolol in pediatric glaucomas: a randomized clinical trial. J Aapos. 2008;12:239–246.
   PubMed Web of Science ®Google Scholar
• Brauner SC, Chen TC, Hutchinson T, et al. The course of glaucoma during pregnancy: a retrospective case series. Arch Ophthalmol. 2006;124:1089–1094.
   PubMedGoogle Scholar
• Morris S, Geh V, Nischal K. Topical dorzolamide and metabolic acidosis in a neonate. Br J Ophthalmol. 2003;87:1052–1053.
   PubMed Web of Science ®Google Scholar
• Manufacturer’s information: azopt product monograph. Fort Worth (TX): Alcon Ophthalmics; 1998 [revised 2015 Nov].
   Google Scholar
• Johnson SM, Martinez M, Freedman S. Management of glaucoma in pregnancy and lactation. Surv Ophthalmol. 2001;45(5):449–454.
   PubMed Web of Science ®Google Scholar
• Adamsons IA, Polis A, Ostrov CS, et al.; Dorzolamide Safety Study Group. Two-year safety study of dorzolamide as monotherapy and with timolol and pilocarpine. J Glaucoma. 1998;7:395–401.
   PubMed Web of Science ®Google Scholar
• Hu C-Y, Lee B-J, Cheng H-F, et al. Acetazolamide-related life-threatening hypophosphatemia in a glaucoma patient. J Glaucoma. 2015;24:e31–e33.
   PubMed Web of Science ®Google Scholar
• Lo JS, Pang PM, Lo SC. Efficacy and tolerability of brinzolamide/brimonidine suspension and prostaglandin analogs in patients previously treated with dorzolamide/timolol solution and prostaglandin analogs. Clin Ophthalmol. 2016;10:583.
   PubMed Web of Science ®Google Scholar
• Gandolfi SA, Lim J, Sanseau AC, et al. Randomized trial of brinzolamide/brimonidine versus brinzolamide plus brimonidine for open-angle glaucoma or ocular hypertension. Adv Ther. 2014;31:1213–1227.
   PubMed Web of Science ®Google Scholar
• Greig SL, Deeks ED. Brinzolamide/brimonidine: a review of its use in patients with open-angle glaucoma or ocular hypertension. Drugs Aging. 2015;32(3):251–260.
   PubMed Web of Science ®Google Scholar
• Realini T, Nguyen QH, Katz G, et al. Fixed-combination brinzolamide 1%/brimonidine 0.2% vs monotherapy with brinzolamide or brimonidine in patients with open-angle glaucoma or ocular hypertension: results of a pooled analysis of two phase 3 studies. Eye. 2013;27(7):841–847.
   PubMed Web of Science ®Google Scholar
• Nguyen QH, McMenemy MG, Realini T, et al. Phase 3 randomized 3-month trial with an ongoing 3-month safety extension of fixed-combination brinzolamide 1%/brimondine 0.2%. J Ocul Pharmacol Ther. 2013;29(3):290–297.
   PubMed Web of Science ®Google Scholar
• Richter GM, Coleman AL. Minimally invasive glaucoma surgery: current status and future prospects. Clin Ophthalmol. 2016;10:189–206.
   Google Scholar
• Lusthaus JA, Goldberg I. Emerging drugs to treat glaucoma: targeting prostaglandin F and E receptors. Expert Opin Emerg Drugs. 2016;21(1):117–128.
   PubMed Web of Science ®Google Scholar
• Reardon G, Kotak S, Schwartz GF. Objective assessment of compliance and persistence among patients treated for glaucoma and ocular hypertension: a systematic review. Patient Prefer Adherence. 2011;5:441–463.
   PubMed Web of Science ®Google Scholar
• Sen DF, Lindsley K. Neuroprotection for treatment of glaucoma in adults. Cochrane Database Syst Rev. 2013;2:CD006539.
   Google Scholar
• Doozandeh A, Yazdani S. Neuroprotection in glaucoma. J Ophthalmic Vis Res. 2016;11(2):209–220.
   PubMedGoogle Scholar
• Inoue K, Soeda S, Tomita G. Comparison of Latanoprost/Timolol with carbonic anhydrase inhibitor and Dorzolamide/Timolol with prostaglandin analog in the treatment of glaucoma. J Ophthalmol. 2014;2014:975429.
   PubMed Web of Science ®Google Scholar
• Sun J, Lei Y, Dai Z, et al. Sustained release of brimonidine from a new composite drug delivery system for treatment of glaucoma. ACS Appl Mater Interfaces. 2017;9(9):7990–7999.
   Web of Science ®Google Scholar
• Li H, Liu Y, Zhang Y, et al. Liposomes as a novel ocular delivery system for brinzolamide: in vitro and in vivo studies. AAPS PharmSciTech. 2016;17(3):710–717.
   PubMed Web of Science ®Google Scholar
• Li J, Liu H, Liu LL, et al. Design and evaluation of a brinzolamide drug-resin in situ thermosensitive gelling system for sustained ophthalmic drug delivery. Chem Pharm Bull (Tokyo). 2014;62(10):1000–1008.
   PubMed Web of Science ®Google Scholar